Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GFH009 + Zanubrutinib in R/R DLBCL
NCT06375733Phase 2Recruiting
- Sponsor
- GenFleet Therapeutics
- Start
- Mar 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GFH009 in diffuse large B-cell lymphoma (DLBCL), sponsored by GenFleet Therapeutics. Started Mar 2024; status: recruiting.
02
Drugs
GFH009
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06375733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06375733.